ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy

Lymphoma, B-Cell Clinical Trial

Official title:

A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04121507
• Other study ID #: ASTRAL / GLA-aNHL-R1
• Status: Completed
• Phase: Phase 2
• Start date: June 24, 2019
• Est. completion date: February 2, 2023

Study information

• Verified date: April 2022
• Source: GWT-TUD GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective Phase II clinical study to assess the efficacy and toxicity of high dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (allo- or autoSCT) as treatment of primary progressive and relapsed aggressive Non-Hodgkin Lymphoma (NHL) - ASTRAL

Description:

This is a clinical study to assess the treatment (efficacy and toxicity) with a high dosed chemotherapy followed by stem cell transplantation in patients suffering from primary progressive and relapsed aggressive Non-Hodgkin Lymphoma (NHL)

After end of the active study phase, patients will receive further standard medical care at the discretion of the treating physician. The clinical consultants will provide advice on further treatment if requested.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: February 2, 2023
• Est. primary completion date: March 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subjects must fulfill all of the following criteria to be included in this trial:

1. Provision of written informed consent and specifically the consent to the collection and processing of health-related data

2. Age: 18 years and older

3. Gender: Male and female patients

4. Histology

5. Diagnosis of relapsed or primary progressive aggressive B- or T-cell lymphoma including:

1. B-Cell non-hodgkin lymphoma (B-NHL) or

2. T-Cell non-hodgkin lymphoma (T-NHL):

6. Staging at relapse or progression (data should not be older than 4 weeks):

7. Staging after 2 or 3 cycles of salvage treatment:

8. Donor availability:

9. Females of childbearing potential (FCBP) must:

• Understand the potential teratogenic risk to the unborn child

• Understand the need and agree to utilize two reliable forms of contraception

• Understand and agree to inform the investigator if a change or stop of method of contraception is needed

• Be capable of complying with effective contraceptive measures

• Be informed and understand the potential consequences of pregnancy and the need to notify her study doctor immediately if there is a risk of pregnancy

• Understand the need to commence the study treatment as soon as study drug is dispensed following a negative pregnancy test

• Understand the need and accept to undergo pregnancy testing based on the frequency outlined in this protocol

• Agree to abstain from breastfeeding during study participation

10. Males must:

• Agree to use a latex condom during any sexual contact with females of childbearing potential

• Agree to refrain from donating semen or sperm while on the study drugs and should seek for sperm cryopreservation before therapy is started and should not father a child while treated and during one year after end of study treatment

11. Females of non-childbearing potential:

Exclusion Criteria:

Subjects are to be excluded from the study if they display any of the following criteria:

1. Pregnant females; lactating women must end breast feeding before start of study treatment

2. Serious accompanying disorder or impaired organ function

3. Central nervous system (CNS) involvement of lymphoma - to be examined in case of clinical symptoms

4. History of severe cardiac diseases, and cardiac function impairment

5. Severe kidney disease

6. HIV-positivity

7. Hepatitis B and C as defined by seropositivity

8. Patients under legal guardianship regarding medical decisions

9. Ongoing treatment or study procedures within any other clinical trial with the exception of follow up

10. Ongoing exclusion periods of other clinical studies after end of treatment

11. In patients tested: Metabolic Computer tomography (CR) in a positron emission tomography-Computer tomography (PET-CT) scan after the last cycle of therapy prior to planned SCT

12. Subjects with known hypersensitivity to the study drugs

13. Criteria which in the opinion of the investigator precluded participation for scientific reasons, for reasons of compliance, or for reasons of the subject's safety

14. Commitment to an institution by virtue of an order issued either by the judicial or the administrative authorities

15. Dependency on the sponsor, trial site or investigator

16. Additional exclusion criteria with respect to summary of product characteristics (SmPC) of the investigational medical product (IMPs) fludarabine, thiotepa, cyclophosphamide:

1. Known hypersensitivity to fludarabine, thiotepa, cyclophosphamide or one of their metabolites

2. Renal impairment

3. Decompensated haemolytic anaemia

4. Concurrent application of vital vaccines

5. Cystitis

6. Renal tract obstruction

7. Active and uncontrolled infection

8. Notice: myelosuppression and impaired hematopoietic function is not an exclusion criterion as this usual contraindication to the application to any of the IMPs will be overcome by the stem cell transplantation following conditioning therapy.

-

Related Conditions & MeSH terms

• Aggression
• Aggressive Non-hodgkin Lymphoma (aNHL)
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Non-Hodgkin
• Lymphoma, T-Cell

Intervention

Drug:
• High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)
High-dose therapy (HDT) prior to alloSCT will consist of FTC

Procedure:
• Bone marrow histology
Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved

Diagnostic Test:
• clinical and laboratory parameters
During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.
• PET-CT or CT
Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.

Locations

Country	Name	City	State
Germany	Klinikum Augsburg, Medizinische Klinik II	Augsburg
Germany	HELIOS Klinik Berlin-Buch, Klinik für Hämatologie und Stammzelltransplantation	Berlin	Brandenburg
Germany	Medizinisches Universitätsklinikum	Bochum
Germany	Klinikum Chemnitz gGmbH	Chemnitz
Germany	Universitätsklinikum Carl Gustav Carus Dresden, Medzinische Klinik I	Dresden
Germany	Universitäsklinikum Düsseldorf	Düsseldorf
Germany	Universitätsmedizin Göttingen Klinik für Hämatologie/Med. Onkologie	Göttingen
Germany	Universitätsklinikum Halle	Halle
Germany	Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie, Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation	Hamburg
Germany	Universitätsklinikum Heidelberg, Medizinische Klinik, Innere Medizin V	Heidelberg
Germany	Universitätsklinikum Jena, Klinik für Innere Medizin, Abtl. Hämatologie und Innternistische Onkologie	Jena
Germany	Universitätsklinikum Münster, KMT-Zentrum/ Med. Klinik A	Münster
Germany	Klinikum Stuttgart	Stuttgart

Sponsors (1)

Lead Sponsor	Collaborator
GWT-TUD GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of efficacy variables, Rate of Progression free survival (PFS)	To compare a defined high dose therapy (HDT) with study medication followed by alloSCT lead to treatment results in terms of PFS, that are better than results obtained with high-dose therapy and autoSCT in a comparable Patient Population ( historical data).	1 year after SCT
Secondary	Measurement of efficacy variables, Rate of complete remissions (CR)	Number of complete remissions divided by the number of patients (CR),	1 year after stem cell transplantation (SCT)
Secondary	Measurement of efficacy variables, Rate of partial remissions (PR)	Number of partial remissions divided by the number of patients (PR);	1 year after SCT
Secondary	Measurement of efficacy variables, Rate of complete and partial remissions (ORR)	Number of complete and partial remissions divided by the number of patients (ORR);	1 year after SCT
Secondary	Measurement of efficacy variables, Rate of progressive diseases (PD)	Number of progressive diseases after SCT divided by the number of patients (PD);	1 year after SCT
Secondary	Measurement of efficacy variables, Rate of relapse (RR)	safety item	1 year after SCT
Secondary	Measurement of efficacy variables, Rate of treatment-related mortality	treatment-related death divided by the number of patients	1 year after SCT
Secondary	Rate of event free survival at 1 year (EFS)	safety item	1 year after SCT
Secondary	Measurement of efficacy variables, Rate of overall survival at 1 year (OS)	safety item	1 year after SCT
Secondary	Measurement of efficacy variables, Rate of non-relapse mortality (NRM)	safety item	1year after SCT
Secondary	Measurement of efficacy variables, Causes of death	safety item	1year after SCT
Secondary	Measurement of efficacy variables, Incidence and severity of acute and chronic graft versus host disease (GvHD);	safety item	until the last Follow-Up Visit ( 1-2 Year after SCT)
Secondary	Measurement of efficacy variables, Adverse events (AEs) grade 3 and 4	safety item	until about day 100 after SCT.
Secondary	Measurement of efficacy variables, Serious adverse events (SAEs)	safety item	until about day 100 after SCT.
Secondary	Measurement of number of blood cells	recovery of White blood cells and platelets	1year after SCT
Secondary	Measurement of efficacy variables, Rate of infections	safety item	1year after SCT